Kornimate/medical-research-clean huggingface dataset:
dnr and arac combined to fractionated mylotarg® in patients with first relapse of aml

Conditions: Acute Myeloid Leukemia

Summary: for several years, the effective standard induction chemotherapy for aml has been limited to the association of anthracycline and aracytine. go is the first effective targeted antibody used in leukemia patients. in a previous study, we showed efficacy and safety of fractionated doses of go used as a single agent for treatment of adult aml patients in first relapse. in the present study the possibility of combining fractionated doses of go to escalated doses of a 3+7 regimen old is studied in relapsed aml patients \> 50 and \<70 years.

induction course are: go 3mg/m2 on days 1, 4,7 + the three dose levels were as follows: level 1: dnr: 45 mg/m2 x 3 days + arac: 100 mg/m2 x 7 days level 2: dnr: 60 mg/m2 x 3 days + arac: 100 mg/m2 x 7 days level 3: dnr 60 mg/m2 x 3 days + arac: 200 mg/m2 x 7 days. with 20 mg of methylprednisolone prior to each go infusion. consolidation course: patients in cr may receive 2 additional courses of consolidation chemotherapy with amsacrine 90 mg/m2 daily for 3 days, and ara-c (1g/m2/12 hours x 3 days) + go 3 mg/m2 on day 1. treatment with hsct is offered at the discretion of the physician in charge of the patient. a delay between last infusion of go and hsct above 3 months is recommended

Eligibility criteria:
inclusion criteria: patients with a morphologically proven diagnosis of cd33-positive aml and : 1. age ≥ 50 years and ≤ 70 years. 2. first relapsing aml with a duration of first cr ≥ 3 and ≤18 months 3. ecog performance status 0 to 3 4. negative serology hiv, hbv and hbc (except post vaccination) 5. serum creatinine ≤ 2n; ast and alt ≤ 2n; total bilirubin ≤ 2n 6. cardiac function determined by radionuclide or echography within normal limits. 7. negative serum pregnancy test within one week before treatment for women of child bearing potential 8. signed informed consent. exclusion criteria: 1. m3-aml 2. aml following diagnosed myelodysplastic syndrome or myeloproliferation 3. known central nervous system involvement with aml 4. prior treatment with hsct. 5. previous treatment with anti cd33 antibodies 6. uncontrolled infection 7. other active malignancy

Keywords: acute myeloid leukemia first relapsing aml
korean coronary overlapping stenting registy

Conditions: Coronary Artery Disease

Summary: the korean coronary overlapping stenting registry is a multicenter database which includes percutaneous intervention using drug-eluting stents from cardiovascular centers in eight affiliated hospitals of the catholic university of korea

the korean coronary overlapping stenting registry is a multi-center, real-world of drug-eluting stent overlap.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * drug-eluting stent overlap exclusion criteria: * overlap with previous stent * cardiogenic shock
ultrasound probe pressure on the intratendon doppler signal in patellar tendinopathy

Conditions: Patellar Tendinitis

Summary: in the sports field, patellar tendinopathy is, as a pathology, one of the main concerns for athletes, both because of its incidence and because of the difficulty involved in their recovery. at the ultrasound level, tendinopathies can be divided, depending on the presence or absence of an intratendon doppler signal, into hypervascular or hypovascular tendinopathy. its classification is, today and clinically speaking, merely qualitative through the observation of the explorer. the ultrasound evaluation is carried out through a probe that is placed on the patient's skin, the procedure to be followed to obtain a vascular image is merely operator-dependent, that is, the position of the probe, the pressure exerted on the skin or even ultrasound optimization parameters can drastically modify the results. due to high pressure on the probe, the intratendon doppler signal may be diminished in the quantitative variables of area, number of signals, pixel intensity, perimeter, solidity, perfusion index, circularity, major and minor diameter. from a certain pressure on the probe, the intratendon doppler signal can be drastically altered. this study will try to evaluate the influence of the pressure exerted by the examiner with the probe on the quantitative variables of the intratendon doppler signal in patellar tendinopathy. to carry out the study, a single group with patellar tendinopathy will be established. ultrasound evaluations with doppler mode will be performed on the tendon using different probe pressures, monitoring the applied force and recording the images obtained for later analysis.


Eligibility criteria:
inclusion criteria: * acceptance of participation in the study. * diagnosis of patellar tendinopathy with the presence of an intratendon doppler signal. * subjects between the ages of 18 and 65. exclusion criteria: * present some type of surgical intervention in the region to be explored that could alter in some way the ultrasound evaluation. * refer vascular pathology or the intake of medication that may alter blood flow or density. * having been treated with sclerosing techniques that can alter the perfusion or vascular resistance of the tendon tissue.
ventricular remodeling and heart failure after myocardial infarction: a community study

Conditions: Heart Failure; Myocardial Infarction

Summary: to comprehensively characterize left ventricular (lv) remodeling after myocardial infarction (mi) in the community, study the association between patterns of remodeling and biological pathways and examine the association between the predictors of remodeling and heart failure after myocardial infarction.


Eligibility criteria:
inclusion criteria: 1. hospitalized patients with a clinical diagnosis of myocardial infarction. 2. residents of olmsted, dodge, goodhue, wabasha, winona, fillmore and mower counties. 3. able to provide informed consent. exclusion criteria: 1. previous clinical diagnosis of myocardial infarction 2. previous diagnosis of heart failure and/or cardiomyopathy 3. diagnosis of apical ballooning syndrome 4. planned coronary artery bypass graft (cabg) during index hospitalization 5. unable to provide informed consent
pharmacokinetics and safety study of me1111 in moderate to severe onychomycosis patients

Conditions: Onychomycosis

Summary: this study is randomized, double-blind, vehicle-controlled, multiple-dose study. the purpose is to determine the safety, tolerability, systemic exposure and pharmacokinetics of me1111 after repeated daily topical application of me1111 in a maximal use setting in adults with distal subungual onychomycosis of the toenails.


Eligibility criteria:
inclusion criteria: 1. male or female of any race and between the ages of 18 and 70 inclusive 2. clinically diagnosed onychomycosis of the target nail 3. presence of moderate to severe distal subungual onychomycosis 4. a positive potassium hydroxide(koh) microscopy test result 5. a positive fungal culture for a dermatophyte 6. females of childbearing potential must be using a highly effective method of birth control and be willing to remain on the same method of birth control throughout the study 7. good general health as determined by the investigator based on the subject's medical history and physical examination exclusion criteria: 1. clinical significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize subject's safety 2. subjects with a history of diabetes mellitus 3. unwilling to refrain from the use of nail cosmetics such as clear and/or colored nail solutions 4. females who are nursing, pregnant, or planning a pregnancy during the study 5. failure to complete the specified washout period(s) for the following topical medications: antifungals drugs within 4 weeks; anti-inflammatory drugs, corticosteroids, immunomodulators within 2 weeks 6. failure to complete the specified washout period(s) for the following systemic medications: corticosteroids within 2 weeks; antifungals for treatment of onychomycosis or any antifungal with known activity against dermatophyte within the previous 24 weeks or 5 half-lives of the drug, whichever is longer; immunomodulators within 4 weeks 7. history of cardiac disease and cardiac arrhythmic activity, or prolonged qt interval 8. received treatment for any type of cancer within the last 6 months 9. history of any significant disease or disorder that might put subjects at risk by participating in study or influence results of study 10. nail or anatomic abnormalities of the toe 11. positive test for hiv, hepatitis b or hepatitis c 12. history of street drug or alcohol abuse 13. donated or lost blood or participated in a clinical study which involved the withdrawal of a large volume of blood (500 ml or more), within the last 6-week 14. participated in any other trial of an investigational drug or device within 30 days or 5 half-lives of the investigational drug or participation in a research study concurrent with this study 15. unable to communicate or cooperate with the investigator due to comprehension, mental development, or impaired cerebral function 16. presence of any underlying disease that the investigator deems uncontrolled, and poses a concern for the subjects safety while participating on the study
effects of sedatives on sublingual microcirculation of patients with septic shock

Conditions: Shock,; Sepsis

Summary: previous studies have demonstrated that altered microvascular blood flow is an important marker of severe sepsis. usually, these patients need invasive ventilatory support, frequent use of sedatives and it is unknown if these agents interfere or not on microvascular blood flow. the goal of this study was to compare effects of propofol and midazolam infusions on sublingual microcirculation of septic shock patients.


Eligibility criteria:
inclusion criteria: * septic shock patients needing mechanical ventilation in pressure or volume-controlled mode. exclusion criteria: * age less than 18 years, * pregnancy, * non-sinus rhythm, and * contraindication of daily interruption of sedative drug, * mainly with the use of neuromuscular blocking drugs, or * patients with intracranial hypertension or epileptical status.

Keywords: microcirculation hypnotics and sedatives, propofol, midazolam
effects of rac with locomotion training on cortical excitability and behavior in patients with pd

Conditions: Parkinson's Disease

Summary: in this study, 51 subjects include 17 freezers,17 non-freezers and 17 aged-matched healthy subjects will be recruited. we will compare the cortical excitability, gait performance, and stepping-in-place performance before and after intervention of auditory cues combined with gait training. the cortical excitability will be assessed by transcranial magnetic stimulation (tms). the purpose in this study is to investigate the effects of auditory cues with gait training on cortical excitability and rhythmic movements in patients with parkinson's disease.

background: parkinson's disease is a common neurodegenerative disease and movement disorder. due to the degeneration of basal ganglia, patients with parkinson's disease also demonstrate internal rhythm dysfunction, thus will lead to difficulty in rhythmic movements such as ambulation. to improve the rhythmic movement problems, auditory cues are often used in clinical setting and have been revealed providing benefits in ambulation and freezing problems for pd subjects. besides, treadmill training is another common intervention to improve gait performance for pd. however, lack studies investigate the effects of auditory cues with locomotion training on brain neurophysiology and scarcer studies investigate the different effects of auditory cues between the freezers and non-freezers. objective: to investigate the effects of auditory-cued training on cortical excitability and motor performances in patients with pd. to investigate whether different effects of auditory cues on cortical excitability and motor performance between the freezers and non-freezers. methods: we will recruit 17 freezers, 17 non-freezers and 17 healthy elderly. each participants will receive the trainings under two conditions in random order. there is one week wash-out period between two-trainings. two-training are (1) treadmill training with concurrent auditory cues: participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min. (2) treadmill training without any auditory cues: participants should walk in comfortable speed on the treadmill for 30 min. assessments consist of cortical excitability through transcranial magnetic stimulation (tms), stepping-in-place test, and walking test, and they will be done before and after training.

Eligibility criteria:
inclusion criteria: * aged above 20 y/o * diagnosed with idiopathic parkinson's disease * no hearing impairment * able to walk independently without aid * mmse above 24 exclusion criteria: * other neurological disease * orthopedic problems affect gait performance * psychological disorder * unstable cardiovescular and respiratory status * dementia * visual disturbance affects gait performance * contraindication of transcranial magnetic stimulation: family history of epilepsy; head injury; head surgery or metal implant; pacemaker; syncope or migraine with unknown reasons; pregnancy

Keywords: pd auditory cueing tms
dcb treatment in cto guided by ivus

Conditions: Coronary Artery Disease

Summary: the percutaneous coronary intervention (pci) for chronic total occlusion (cto) coronary artery disease is difficult, the success rate is low, and the incidence of re-occlusion and restenosis is high. with the wide application of imaging technology represented by intravascular ultrasound (ivus), the success rate of cto pci has been significantly improved. drug-coated balloons (dcb), as a treatment without metal implantation, has lower lumen loss and no significant increase in the rate of revascularization. through ivus measurement of vascular lumen after cto opening, appropriate instruments can be selected for adequate dilation, and appropriate treatment methods can be selected according to different lumen structures. therefore, the purpose of this study was to evaluate the clinical effect of ivus-guided dcb therapy on cto lesions.


Eligibility criteria:
inclusion criteria: 1. over the age of 18, male or female; 2. patients who meet the diagnostic criteria for coronary heart disease, have clinical symptoms and seek interventional treatment; 3. coronary angiography confirmed that the blood vessels met the diagnostic criteria of cto; 4. sign informed consent and be willing to undergo follow-up for at least 12 months. exclusion criteria: 1. patients with severe contrast allergy who cannot tolerate coronary angiography; 2. patients known allergy to drug balloon coating; 3. patients who is pregnant or breastfeeding; 4. bleeding or other diseases, such as digestive tract ulcers, blood system diseases, etc., limit the use of platelet aggregation inhibitors and anticoagulation therapy; 5. patients with cardiac shock; 6. patients with a life expectancy of less than 1 year; 7. other situations deemed unsuitable for inclusion by the researcher.
community-based diabetes care for korean american immigrants

Conditions: Type 2 Diabetes

Summary: the primary aims are to test the effectiveness of the self-help dm intervention (ship-dm), a comprehensive, culturally tailored dm management intervention, in improving glucose outcomes; to determine the effectiveness of the ship-dm in kai with type 2 dm in improving self-care skills and psycho-behavioral outcomes related to dm control, to develop tangible infrastructures for the dissemination of valid and effective education materials to a wider population of kai with type 2 dm in the us (e.g., audio-visual education materials, web-based intervention materials, mobile telephone-based intervention materials) and to explore the feasibility and acceptability of each dissemination module, utilizing the delayed intervention group participants. the secondary aims are to obtain preliminary cost-effectiveness data related to the proposed intervention, including cost estimates for this type of dm intervention, and to establish a systematic, long-term dissemination plan, including documenting effective methodologies, to facilitate faster translation of research findings and products to direct consumers in non-research settings.

inclusion criteria 1. self-identified as a first generation korean american 2. type 2 diabetes 3. age 30-75 years 4. resides in washington-baltimore area 5. self-identified with dm and hba1c \>= 7.0 % within 6 months of screening 6. expresses willingness to participate in all aspects of the study over its full course exclusion criteria 1. unable to give informed consent 2. physical or mental health conditions that could limit active participation in the study (e.g., blindness in both eyes, severe immobility, psychiatric diseases) 3. hematological condition that would affect a1c assay, e.g., hemolytic anemia, sickle cell anemia 4. past experience in diabetes group education

Eligibility criteria:
inclusion criteria: 1. self-identified as a first generation korean american 2. type 2 diabetes 3. age 30-75 years 4. resides in washington-baltimore area 5. self-identified with dm and hba1c \>= 7.0 % within 6 months of screening 6. expresses willingness to participate in all aspects of the study over its full course exclusion criteria: 1. unable to give informed consent 2. physical or mental health conditions that could limit active participation in the study (e.g., blindness in both eyes, severe immobility, psychiatric diseases) 3. hematological condition that would affect a1c assay, e.g., hemolytic anemia, sickle cell anemia 4. past experience in diabetes group education

Keywords: korean american, type 2 diabetes, culturally tailored
adult subjects with uncontrolled type 2 diabetes

Conditions: Type 2 Diabetes

Summary: a multi-center, double blind, randomized, placebo-controlled, parallel group phase iia study of mlr-1023 in adult subjects with uncontrolled type 2 diabetes

objectives 1. to assess the safety, tolerability and initial anti-diabetic activity of mlr-1023 in subjects with uncontrolled mild to moderate type 2 diabetes mellitus 2. to evaluate the pharmacokinetics of mlr-1023 and the major metabolite, mlr-1023-m1 following 28 days of repeat dosing design and outcomes the study is a randomized, double blind, placebo-controlled, parallel group study of mlr-1023 in adult subjects with uncontrolled type 2 diabetes mellitus who are on diet and exercise therapy. a subset of subjects per dose group will have additional samples analyzed to measure signs of mlr-1023.

Eligibility criteria:
inclusion criteria: 1. diagnosed with uncontrolled t2dm who have received diet and exercise therapy for at least 3 months prior to screening, aged ≥ 18 - ≤ 75 years 2. females must be post-menopausal, unable to conceive, or test negative for pregnancy via blood test and use barrier contraception 3. bmi ranging from ≥ 20 to ≤ 40 kg/m2 4. fasting plasma glucose values of up to 240 mg/dl at screening, after wash-out (visit 2) and after placebo run-in (visit 3) 5. (i) naïve or (ii) currently using and discontinued metformin or (iii) no prior exposure to anti-diabetic agents other than metformin ≥ 6 months prior to screening exclusion criteria: 1. history of type 1 diabetes 2. history of more than 1 episode of severe hypoglycemia within 6 months prior to screening, or a current diagnosis of hypoglycemia unawareness. 3. hospitalizations or emergency room visits that would impact patient safety or data interpretation: 1. due to poor glucose control in the 6 months prior to screening or 2. any bariatric surgical procedures for weight loss. 4. significant change of body weight (\>10%) in the 3 months before screening 5. proliferative retinopathy or maculopathy within the 6 months before screening or requiring acute treatment, or severe neuropathy
a dose-escalation study of lipotecan® plus radiotherapy in locally advanced hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: radiotherapy (r/t) for locally advanced hepatocellular carcinoma (hcc) is often used in patient who is not suitable for transarterial chemoembolization (tace) and other local therapy, especially in those with portal vein tumor thrombosis (pvtt) caused by tumor cells. several previous studies have showed that local r/t is tolerable and can induce a substantial tumor response in hcc management. in addition, the safety, toxicity and preliminary efficacy of lipotecan® (tlc388) has also been proved in patients with terminal malignancy. this study aims to evaluate the safety, tolerability and efficacy of concomitant lipotecan® and radiotherapy in patients with locally advanced hcc and pvtt.

lipotecan® is a drug product of tlc388 hcl, which is a potent camptothecin analog with cytotoxic activities against a variety of human tumor cell lines and anti-tumor activities in several xenograft models with human tumor cell lines. structurally, tlc388 hcl is related to other camptothecins, but it has been chemically modified to improve stability and potency, and to minimize toxicities.

Eligibility criteria:
inclusion criteria: * females or males 20-70 years of age (inclusive) * patients with histological confirmed hcc or other conditions * patients with locally advanced hcc and pvtt that is not suitable for other local therapies * other inclusion criteria also apply exclusion criteria: * females who are pregnant/lactating or planning to be pregnant, or patients of childbearing potential who are not using medically recognized method of contraception. * patients with documented extrahepatic metastasis * patients with stage iii-iv encephalopathy or tense ascites * patients who have received any local or systemic therapy for hcc within 4 weeks prior to the initiation of study treatment * patients who have received lipotecan® treatment prior to the initiation of study treatment * other exclusion criteria also apply

Keywords: hcc pvtt
comparison of post-operative symptoms after two surgeries for patients with pelvic organ prolapse

Conditions: Pelvic Organ Prolapse

Summary: collect and review the patients who underwent surgical treatment due to pelvic floor organ prolapse from 2020 to 2021, make statistics on their postoperative questionnaire data, and evaluate the clinical effects of different surgical methods


Eligibility criteria:
inclusion criteria: * age ≥ 30 years; * because pelvic organ prolapse in our hospital, we performed extraperitoneal high sacral ligament suspension or sacrospinal ligament fixation; ③ those who have no surgical contraindication and can tolerate surgery and anesthesia. exclusion criteria: * those who cannot tolerate surgery and anesthesia; ② patients receiving other tip suspension techniques.